skip to Main Content

This page is designed to provide you with an array of useful resources including articles, accounts from healthcare professionals, calls for abstracts and statements related to COVID-19 and the liver.
You are welcome to send us relevant articles, links and testimonies from healthcare workers for us to share once we’ve curated them.
Please send your materials to marcomms@easloffice.eu

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper


In response to the COVID pandemic, EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) –  have issued a Position Paper providing recommendations for clinicians on caring for patients with liver diseases and for liver transplant recipients.

In addition to recommendations, this Position Paper provides a flowchart and an overview of current treatment options, to help clinicians with their decision-making during this resource-strapped time of COVID-19.

EASL webinars & webcasts

EASL has launched a series of webinars and webcasts relating to COVID-19. The participants are world-renowned scientists and clinicians that discuss and share their knowledge about the latest developments of the virus.

Webinar 1: EASL – WHO on COVID-19 and the Liver

A special webinar on COVID-19 and the liver organised by EASL and the World Health Organization (WHO). A panel of leading international experts and clinicians in hepatology and virology present the latest information on the COVID-19 pandemic, the WHO response, and how the pandemic is affecting the care of people with liver disease and viral hepatitis, both from a clinical and public health perspective. The panel hears directly from front-line clinicians and programme managers from different countries on their experiences in the COVID-19 national response, and in managing the impact on hepatitis services during the current crisis.

Webcast 1: Virological Aspects of COVID-19

In this first edition of EASL’s webcast series on COVID-19, Prof. Darius Moradpour will take you through the fundamentals of the SARS-CoV-2 virus, the cause of COVID-19, supported by two world-renowned virologists: Prof. Jan Felix Drexler and Prof. Volker Thiel. This webcast sets the scene for future episodes that will cover the clinical aspects of COVID-19 and will update on what we know regarding the hepatic effects of this virus. Stay tuned for the next ones.

Webcast 2: Viral markers and the diagnosis of COVID-19

Join Prof. Mario Mondelli and Prof. Jean-Michel Pawlotsky for a two-part discussion on viral markers in COVID-19 and how they relate to diagnosis and public health.

In part one, the experts take an overview of how the viral markers change over the course of the infection, and what this tells us about the infectiousness of this virus at different stages. They examine how RNA and antibody markers for the virus can be combined to arrive at a diagnosis for COVID-19, and reflect on the reliability of sampling methods such as nasopharyngeal swabs.

Webcast 3: Viral testing and the immune response to COVID-19

Following up on their last conversation for the EASL COVID-19 webcast series, Prof. Mario Mondelli and Prof. Jean-Michel Pawlotsky explore how RNA and antibody tests can be combined with different testing strategies to arrive at potential exit strategies from the social restrictions in place in many countries. They also highlight likely barriers and challenges to these strategies, from resource limitations to the reliability of the tests themselves.

Testimonials on dealing with the public health crisis

Prof. Jessica Zucman-Rossi

Open access publishing under COVID-19: Working swiftly, yet cautiously

Prof. Jessica Zucman-Rossi

JHEP Reports
Paris, France


Michelle Clayton

Celebrating the adaptable liver nurse: Now and beyond COVID-19

Michelle Clayton

Liver Nurse Educator, Leeds Liver Unit
Lecturer in Adult Nursing, University of Leeds
Chair, EASL Nurses and Allied Health Professionals Task Force
Leeds, UK



COVID-19 and research: Through crisis to progress

Dr Emma R. Andersson

Principle Investigator
Karolinska Institutet
Solna, Sweden



From hepatology to COVID-19 crisis management in France

Prof. Pierre-Emmanuel Rautou

EASL Scientific Committee member
University of Paris-Diderot and Hôpital Beaujon of Clichy
Paris, France



Italian nurses showing their colours:
“I am smiling at you
through my mask”

Hepatology nurse Pamela Ballotta

Multivisceral Transplant Unit and Unit of Gastroenterology
Azienda Ospedaliera di Padova
Padova, Italy



From the epicentre of Italy’s pandemic:
Take care and keep steady

Prof. Luca Valenti

EASL Scientific Committee member
Associate Professor of Internal Medicine, University of Milan

Milan, Italy


COVID-19 related papers from the Journal of Hepatology and JHEP Reports

The “EASL COVID-19 article collection” contains articles dealing with COVID-19 and the liver published in the two EASL journals, Journal of Hepatology and JHEP Reports. This initiative aims at facilitating access to research that can be critically relevant for the treatment of liver patients during the pandemic.

The articles will appear in the collection shortly after their publication in their respective journals.

Read the EASL COVID-19 papers.

News from the EASL supported COVID-Hep registry

Press release, 21/05/2020

A new international study has found increased mortality rates from COVID-19 among people with chronic liver disease and cirrhosis and has called for patients with worsening liver function to be tested for coronavirus.

The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry (the EASL supported COVID-hep registry) to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19. Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95% of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called decompensated cirrhosis had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.

Read more.

The EASL supported COVID-Hep registry was launched on 23 March 2020. EASL is actively supporting this initiative: http://covid-hep.net

Accordingly, EASL encourages healthcare professionals to share the EASL supported COVID-Hep registry among its networks. The new registry was launched at the University of Oxford, UK to collect data on patients, with liver disease at any stage or liver transplants, that have developed laboratory-confirmed COVID-19.

The registry is sending weekly updates on submissions received. Busy healthcare workers are submitting data for patients, with liver disease at any stage or liver transplants, that have developed laboratory-confirmed COVID-19.

As of 26 May, week 9 data collected (combined with data from SECURE-cirrhosis, who are covering the Americas, China, Japan, and Korea) has grown to  649 cases  reported from 30 countries. 

Download the full report from week 9. On 21 May, a study based on the first 152 consecutive submissions was published in the Journal of Hepatology.

For more information or to make a submission via an easy online form, visit COVID-Hep. You can also request updates by email.

Read more

Webinars on COVID-19 and the liver

The APASL Steering Committee is pleased to launch APASL COVID-19 Webinars, a series of seven webinars drawing on the experience of doctors from the Asian Pacific, who faced COVID-19 in this region before it reached other parts of the world. The webinars are intended for these doctors to share their experience with their international peers, to help combat the disease.

Find out on this link all the information about APASL webinars. The webinars are set to run until July 2020.

Discover here all the AASLD COVID-19 RESOURCES

Journal of Hepatology call for papers on COVID-19

The outbreak of COVID-19 (coronavirus) is of great concern and a considerable challenge for practitioners and public health authorities. Following the initiative of other leading scientific journals, we believe that it is timely, important, and appropriate to share with our Journal of Hepatology readers, as soon as possible, all information available on the possible impact of the infection on the liver and on patients with liver diseases.

We therefore invite authors to send their original data on these topics. We will provide authors with a rapid evaluation and, if their articles are accepted, free access to their content. Of course, as an obligation to our community, we will ensure the same high standards of scientific review for these articles.

Read more

External resources on COVID-19


Public health resources

European Centre for Disease Prevention and Control: COVID-19
European Centre for Disease Prevention and Control: today’s data on geographic distribution of COVID-19 cases worldwide
European Commission: Coronavirus response
European Commission: Public health
European Medicines Agency: Coronavirus disease (COVID-19)
World Health Organization: Coronavirus disease (COVID-19) outbreak
World Health Organization: Coronavirus disease (COVID-19) Pandemic 
World Health Organization: Q&A on coronaviruses (COVID-19)

Curated resources

British Medical Journal: Coronavirus (covid-19): Latest news and resources
Cell Press: COVID-19 Resource Hub
The Lancet: COVID-19 Resource Centre
New England Journal of Medicine: Coronavirus (Covid-19)
Science: Coronavirus: Research, Commentary, and News

COVID-19 and the liver

The Lancet: COVID-19 and the liver: little cause for concern
The Lancet: Liver injury in COVID-19: management and challenges
Wiley Online, Liver International: Liver injury during highly pathogenic human coronavirus infections

Open access scientific articles

Cell.com: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Journal of Clinical Microbiology: The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options
Nature: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus
Nature: Epidemiological data from the COVID-19 outbreak, real-time case information
Nature: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

BioMed Alliance submits Joint Statement to EU leaders, as COVID-19 threatens medical associations


Subsequent to the disruption caused by the COVID-19 pandemic, EASL and 32 other leading European medical associations – together forming the Biomedical Alliance in Europe (BioMed Alliance) – have submitted a joint statement to EU leaders.

Read more 

Latest news from the community

An amazing team effort by members of the @LITMUS_IMI consortium. Thanks to all that have worked tirelessly on this effort. Better #biomarkers to improve #nash patient care and support clinical trials - more to come! #livertwitter @NIHRNewcBRC @EASLnews @NCL_medresearch @EFPIA https://twitter.com/litmus_imi/status/1265203145539571712

Biliary cancer studies in all journals confirm the growing attention to such dismal entities with increasing incidence @CcaEns @ILCAnews @AASLDtweets @EASLnews @aeeh https://twitter.com/NCI_Bogler/status/1263856105882390528

LITMUS has successfully achieved two major #biomarker qualification milestones for #NAFLD #NASH trials! @US_FDA accepted our first Letter of Intent (LOI) and we have finalised 2 scientific advice interactions with @EMA_News. @IMI_JU @EASLnews @EFPIA @qanstee

Watch https://youtu.be/2DGvOuyXkh0 to view Prof @RuiCastroHD describing Portugal’s reaction to the #COVID19 crisis: agile, collaborative & innovative. #EASL Viewpoints brings you testimonials from #frontline healthcare professionals & researchers @EASLedu ..

Have you missed our June issue? Read the overview directly From the Editor's Desk…


#HCC, #HEV, #NASH, #cirrhosis

Letter In Press | Marina Serper & colleagues present changes in clinical care of #liverdisease, challenges and opportunities following #COVID19 @PennMedicine

Read full text at http://bit.ly/36oYFuE


@JHepatology Proofs once more that Hepatitis-B vaccine protocol should be amended.
Cirrhosis caused by Hepatitis-B should be something from the past days. We have the arms to fight Hepatitis-B.
Effectiv FDA approved vaccines are available. Please use it.

Editorial from our June Issue - Acute kidney injury in #cirrhosis: An immediate threat but also a ticking time bomb

Full Text at https://bit.ly/36B9pGo
Linked article #openaccess at https://bit.ly/35FHHHO

#ChronicKidneyDisease #ChronicLiverDisease

In our June Issue: Reason to pay attention to the shunt(s)! Praktiknjo et al. performed an international, multicenter study to examine the impact of spontaneous shunts.

Read the results #openaccess at https://bit.ly/2ZEOukj

@JonelTrebicka #cirrhosis

Back To Top